AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to ...

Alphabet and Nvidia offer investors a smart way to get exposure to the AI wave. AbbVie and Interactive Brokers can prove to be resilient long-term picks. All these businesses combine market leadership ...

In an uncertain and volatile market, dividend stocks are often the first choice for investors looking for reliable income.

Let's consider three of them: Eli Lilly ( LLY +0.52%), AbbVie ( ABBV 0.31%), and Intuitive Surgical ( ISRG 1.15%). Here's why ...

Now, it’s worth noting Stock Advisor’s total average return is 955 % — a market-crushing outperformance compared to 196% for ...

Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

AbbVie leads a Zacks Analyst Blog roundup highlighting strong pharma execution, AI-driven chip gains and an aviation rebound.

Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P.

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...